{"url_path":"/sec/dare/10-q/2026/item-5","section_key":"item-5","section_title":"Item 5 Other Information","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-14","source_url":"https://www.sec.gov/Archives/edgar/data/1401914/0001401914-26-000026-index.html","accession_number":"0001401914-26-000026","cik":"0001401914","ticker":"DARE","issuer_name":"Dare Bioscience, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1401914/0001401914-26-000026-index.html","primary_entity_key":"0001401914","primary_entity_name":"Dare Bioscience, Inc."},"word_count":66,"has_tables":true,"body_markdown":"Item 5. Other Information\n\n(a)     None.\n\n(b)     None.\n\n(c)     During the period from January 1, 2026 to March 31, 2026, none of our directors or officers (as defined in Rule 16a-1(f) under the Exchange Act) adopted or terminated any Rule 10b5-1 trading arrangement (as defined in Item 408(a)(1)(i) of Regulation S-K) or any non-Rule 10b5-1 trading arrangement (as defined in Item 408(c) of Regulation S-K).\n\n45"}